NasdaqGM:ATAIPharmaceuticals
Atai Life Sciences (ATAI): Assessing Valuation After New EMP-01 Patent Secures Potential Exclusivity Through 2043
Atai Beckley (ATAI) just secured a new US patent for its EMP-01 oral R-MDMA program in social anxiety disorder, locking in potential exclusivity through 2043 and sharpening the story for long term oriented investors.
See our latest analysis for Atai Beckley.
The patent news lands after a volatile stretch, with the latest share price at $4.29 and a powerful year to date share price return of 168.12% alongside a 1 year total shareholder return of 222.56%. This suggests momentum is still...